Page 1
`
`LUPIN EX. 1027
`Lupin v. iCeutica
`US Patent No. 8,999,387
`
`

`
`F1sH 8c RICHARDSON P.C.
`
`Commissioner for Patents
`
`January 29, 2014
`Page 2
`
`Basic Filing Fee
`
`Search Fee
`
`Examination Fee
`
`Publication fee
`
`Track 1 processing fee
`
`Track I prioritized examination fee
`
`Total Claims 23
`
`over 20
`
`3 X $40
`
`Independent Claims 2
`
`over 3
`
`0 X $210
`
`Fee for Multiple Dependent claims
`
`Application size fee for each 50 pages over 100
`Total Sheets: 127x .75 - 100/50 = 0X
`
`Total Filing fee
`
`$70
`
`$300
`
`$360
`
`$0
`
`$70
`
`$2000
`
`$120
`
`$0
`
`$0
`
`$0
`
`$2920
`
`The filing fee in the amount of $2920 is being paid concurrently herewith on the
`Electronic Filing System (EFS) by way of Deposit Account authorization. Please
`apply all charges or credits to Deposit Account No. 06-1050, referencing Attorney
`Docket No. 31215-001 1003.
`
`If this application is found to be incomplete, or if a telephone conference would
`otherwise be helpful, please call the undersigned at (617) 542-5070.
`
`Page 2
`
`Page 2
`
`

`
`FISH 8c RICHARDSON P.C.
`
`Commissioner for Patents
`
`January 29, 2014
`Page 3
`
`Please direct all correspondence to the following:
`
`26161
`PTO Customer Number
`
`Respectfully submitted,
`
`/Anita L. Meiklejohn/
`
`Anita L. Meiklejohn, Ph.D.
`Reg. No. 35,283
`Enclosures
`
`ALM/mkf
`23l45505.doc
`
`Page 3
`
`Page 3
`
`

`
`PTOIAIAI14 (‘l2-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`3121541011003
`
`Application Number
`
`Title of Invention
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2
`
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`Inventor
`Legal Name
`
`1
`
`Prefix Given Name
`Aaron
`
`Middle Name
`Family Name
`
`Residence Information (Select One) Q US Residency ® Non US Residency 0 Active US Military Service
`CH3’
`Centennial Park, new South Wales
`Ceuntry Of Residence l
`‘AU
`
`Suffix
`
`Mailing Address of Inventor:
`
`368/58 Cook Road
`
`Centennial Park, new South Wales
`2021
`
`StatelProvince
`AU
`
`Address 1
`
`Address 2
`
`City
`Postal Code
`Inventor
`2
`Legal Name
`
`Prefix Given Name
`Felix
`
`Middle Name
`
`Family Name
`MEISER
`
`Suffix
`
`Residence Information (Select One) 0 US Residency @ Non US Residency 0 Active US Military Service
`
`city
`
`Mount Claremont, Western Australia
`
`Ceuntry Of Residence l
`
`AU
`
`Mailing Address of Inventor:
`
`Address 1
`
`T Beecham Road
`
`
`
`
`
`StatelProvince
`
`
`
`AU
`
`Mount Claremont, Western Australia
`
`6010
`
`Address 2
`
`
`
`Postal Code
`Inventor
`3
`Legal Name
`
`EFS Web 2.2.10
`
`P393 4
`
`M
`
`Page 4
`
`

`
`PTOIAIAI14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`
`
` _
`_
`Attorney Docket Number
`31215—O011003
`Application Data Sheet 37 CFR 1.76
`
`Application Number
` Title of Invention
`
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`Prefix Given Name
`Marck
`
`Middle Name
`
`Family Name
`NORRET
`
`Suffix
`
`Residence Information (Select One) 0 US Residency @ Non US Residency 0 Active US Military Service
`
`city
`
`Darlington, western Australia
`
`Ceuntry Of Residence i
`
`AU
`
`Mailing Address of Inventor:
`
`Address 1
`
`26 Stone Crescent
`
`
`
`
`Address 2
`
`
`
`Darlington, western Australia
`
`6070
`
`Postal Code
`Inventor
`4
`Legal Name
`
`Statel'Province
`
`
`
`R
`
`Prefix Middle Name
`
` — RUSSELL
`
`Family Name
`
`Suffix
`
`Residence Information (Select One) 0 US Residency © Non US Residency O Active US Military Service
`
`cm’
`
`Rivervale, western Australia
`
`Countw Of Residence I
`
`AU
`
`Mailing Address of Inventor:
`
`
`Address 1
`
`139 Gladstone Road
`
`Address 2
`
`City
`Postal Code
`Inventor
`5
`Legal Name
`
`Rivervale, western Australia
`6103
`
`State!‘Province
`AU
`
` Prefix Given Name
`Middle Name
`H William
`BOSCH
`
`Suffix
`
`Residence Information (Select One) @ US Residency 0 Non US Residency 0 Active US Military Service
`City
`Bryn Mawr
`StateIProvince
`PA
`country gf Residence i
`| US
`
`
`Mailing Address of Inventor:
`
`237 Rodney Circle
`
`Address 1
`
`
`
`
`
`Address 2
`
`
`State'Pr°vi"°e
`
`
`
`EF5 Web 2.2.10
`
`P393 5
`
`Page 5
`
`

`
`PTOIAIAI14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`
`
` _
`_
`Attorney Docket Number
`31215—O011003
`Application Data Sheet 37 CFR 1.76
`
`Application Number
` Title of Invention
`
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`Inventor Information blocks may be
`Inventors Must Be Listed - Additional
`All
`generated within this form by selecting the Add button.
`
`Add
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR 1.33(a).
`
`|:| An Address is being provided for the correspondence Information of this application.
`
`Customer Number
`
`26161
`
`Email Address Amman
`
`Application Information:
`
`Title of the Invention
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`
` Attorney Docket Number
`
`
`Small Entity Status Claimed
`
`
`Nonprovisional
` Application Type
`
`Utility
`
`
`31215—0011003
`
`Subject Matter
`
`Total Number of Drawing Sheets (if any)
`Filing By Reference:
`
`l 20
`
`l Suggested Figure for Publication (if any)
`
`Only compete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate sectionts) below (i.e., "Domestic Benefit/National Stage |nformation" and "Foreign Priority |nformation").
`
`For the purposes of a filing date under 37 CFR1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`
`
`Intellectual Property Authority or Country i
`
`Publication Information:
`
`|:| Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request N012 t0 Publish. I hereby request that the attached application not be published under
`[1 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`
`Number will be used for the Representative Information during processing.
`
`EFS Web 2.2.10
`
`P393 6
`
`Page 6
`
`

`
`PTOIAIAI14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Title of Invention
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`
`
`
`31215-0011003
`
`Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`Application Number
`
`
`
`Customer Number
`
`
`
`Please Select One:
`
`
`
`@ Customer Number
`
`
`0 US Patent Practitioner 0 Limited Recognition (37 CFR 11.9)
`
`Domestic BenefitINational Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 1l9(e), 120, 121, or 365(c) or indicate National Stage
`entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. l l9(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`Prior Application Status
`
`Pending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`Continuation of
`
`13/266122
`
`2012-02-16
`
`Prior Application Status
`
`Pending
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`13/266122
`
`a 371 of international
`
`PCT/AU2010/000471
`
`2010-04-23
`
`Prior Application Status
`
`Expired
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD)
`
`PCT/AU2010/000471
`
`Claims benefit of provisional
`
`61172291
`
`2009-04-24
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`Add
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(d). When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX) ‘the information will be used by the Office to
`
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate
`
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`Application Number
`2000001740
`Additional Foreign Priority Data may be generated within this form by selecting the
`Add button.
`
`
`
`Filing Date (YYYY-MM-DD)
`
`Remove
`
`Access code‘ (if applicable)
`
`A00
`
`EFS Web 2.2.10
`
`P393 7
`
`Page 7
`
`

`
`PTOIAIAI14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`.
`.
`Application Data Sheet 37 CFR 1.76
`
`Aeemev eeeke Number
`_
`_
`
`Aeeieeeee Nemeer T Title of Invention
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`|:| 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`Authorization to Permit Access:
`
`|:| Authorization to Permit Access to the Instant Application by the Participating Offices
`
`If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO),
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent application—as—filed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)-(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. application—as—filed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date of filing this Authorization.
`
`Applicant Information:
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`
`to have an assignment recorded by the Office.
`
`EF5 Web 2.2.10
`
`P393 3
`
`Page 8
`
`

`
`PTOIAIAI14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`Application Data Sheet 37 CFR 1.76
`
`
`
` Attorney Docket Number
`31215—O011003
`
`Application Number
` Title of Invention
`
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`1
`Applicant
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`Clear
`
`Q Legal Representative under 35 U.S.C. 117
`
`0 Joint Inventor
`
`
`0 Person to whom the inventor is obligated to assign.
`
`O Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`Name of the Deceased or Legally incapacitated Inventor:
`If the Applicant is an Organization check here.
`
`Organization Name
`
`iceufica Pty Ltd
`
`Mailing Address Information:
`
`Address 1
`
`Address 2
`
`Unit 2, 32 Mumford Place
`
`P“°"eN“mbe' —
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Add
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`Assignee
`
`1
`
`Complete this section if assignee information, including non—applicant assignee information, is desired to be included on the patent
`application publication . An assignee—applicant identified in the "Applicant Information'' section will appear on the patent application
`publication as an applicant. For an assignee—applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`
`Remove
`
`|:|
`
`EF5 Web 2.2.10
`
`P393 9
`
`Page 9
`
`

`
`PTOIAIAI14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`
`
`Title of Invention
`
`
`
` Application Data Sheet 37 CFR 1.76
`
`Attorney Docket Number
`
`31215—O011003
`
`Application Number
`
`A NOVEL FORMULATION OF DICLOFENAC
`
`Prefix
`
`
`
`
`
`— S*at°""°vi"°e —
`— P°~=»ta'C°de —
`
`F’“°"e“"mbe' —:
`Email Address
`
`
`
`
`
`
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Signature:
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications
`
`Signature First Name
`
`Date (YYYY-MM-DD)
`
`Registration Number
`
`2014-01-29
`
`35283
`
`/Anita L. Meiklejohn]
`
`Meiklejohn
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`Add
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form andlor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EF5 Web 2.2.10
`
`P393 10
`
`Page 10
`
`

`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant
`to 35 U.S.C. 122(b) or issuance ofa patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the
`USPTO becomes aware of a violation or potential violation of law or regulation.
`
`EFS Web 2.2.10
`
`Page 11
`
`Page 11
`
`

`
`
`
`
`Under ihe Papenwrk Raducficn Anna?‘ 1995. no pa:
`
`P‘:“Q:‘rW‘xI'0‘l (1)6-12)
`F)sfJf5F£}V9E§ for 1.255 througgit’ f.“!.'1's’il2€}'i 4. OMB 0'1-3’5’1
`1..-‘,3. Péafeni ant} Trademark O??‘tce;’ US. DEPARTMENT OF COMMERCE
`c-as are require-.'3»ta respond in 2: coueciiors .r:fin1‘:2mza€isn unless i§d1spIays.a valid OMB -:on':rol number.
`
`
`T EATQN {av gm $.33; ¥ 'm.a*~:* ma:
`>>>H
`AFPM$fi§Kfi§fiRE&SHEEfi?€FR13§}
`
`
` ;:§Ef§,§§m §A gxzovaz. §=:‘:3§-2§.«suLAT‘:oax3 QF £3€CLGFENAC
`E
` As the beéczw named §:*.vez1is)r,
`E hereby deciares that‘:
`
` E?!
`; This ciaa::€a3'a§¢:zn
`The attached appiicatian, or
`Z
`directed ‘:0:
`
`
`
`
`united States am:-iicaiion or PCT iniematéorxéi a.;a3>i$c:aé§:)r3 rsurnber
`fiied on
`
`
`
`
`
`
`
`sea ‘ezhzsve-idéntffied azspéicaiima was made or :aut?::>a'E;~::=.~d.i<.= me made by me.
`
`'
`
`3 beiéeve that i am ifésa ofigginaé §n>:entor at an origifsei jcsim imrentor 9;‘ a ckesianeai Envemtien in the a;3;3§icat§on.
`
`3 hereby acknewiedgeihat any wiéifui faisa Siiafiaffififii rnada in this deciarafion is punishabie under 18 U.S.{3. mm
`by
`or s'm;>rs‘sm1ment of not more than five {5}‘yaea=rs., or 122051.
`
`
`
`
`
`
`
`WARNMSE:
`
`avlnivlvavvav/nrllnlavvml/«viva!.
`
`: E3e'E§i§me:!app2icant is cautioned 'tc3'avo‘::§ sLsE)rs3§ifing persenai informaiion in »:ic:cuments‘f3ie:§ M is patent appiicaiicn that may
`
`
`' ;::mtrihu’te ta kentity {heft Pe.¥~:.0:1a§~2nf»n‘rmaiiosi’ such as sacéai secssrify rs=.emi>ei~a,. bank account numbers, or’cz'ec1§i.sani nuwbew
`other than a check c>:'s:ree:{iEs:1=2rd suéizcsrizaiign fern’: PT{3~2L»‘38 submitted for gsayment purpcss-35}
`never required byiiae USE-‘TO
`
`
`‘ 0 support apetiéiokw Gk‘ an §a§3;‘.s§§<IES3'iC§€‘£.
`ifthis type of’§aers{3na!infom1’atian is inaiucfezd in dectumems submitted ‘to the USPTO.
`‘
`etitianersfappiiczsfiizs szheuité cansidsr rezdacténg such zaersorsai infaarzraatiarz frcmtfize rkscumrsnts befsra submiitfrtg ihem tcythe
`
`§J$P‘§“{).. Peiiticrnariappéicané is scixzisefi tits: the restart?
`2: paieni ap§C:¥émti0n- is ayaiiahfe is the ;)ub§§1:. after ;2ut;_i§:;;atEori of the
`pgsiieatism {uniess a hohwsza,-s§"sE§=.:atie:'s; request in c,tms;>§ia2nce with 3? CFR 1.’-"€3(a)
`is made in the ap;3iica‘£i:m} or issuance 0?‘ a
`atent. Furfldermere, the reczsxrd from 3:‘: abandoned app§icai:3<:n may a§s.<:« be avaisaéyie ta i;h‘e=,‘;;:.t2‘Ioli;:; if the appiicaiien is
`eferencea‘ in :=1.§m'§_3}§:a?sse<:§ agaplicafian or an issued patent {see 3? CFR 1.14). Checks and credit card autharézatiers forms
`5 PTc:)—283>3 su‘::snit{e,a5' far ‘;C23ymenfi‘purpc:::~es are not reiainad £52 five appiicaéion fiie and therefore are mt pubaicfy avzaiiabie.
`
`
`
`
` LE ‘° L NAME amwvawfoa
`
`3:
`Snventorz
`Aar<m_§>o_x72_<§_
`________________ Date cjczptéonai) :
`
`fiignsture:
`:
`
`
`
`2 g
`
`
`
`Noie: An appiicafion fiata she.et,{PTOiSBf14 9:’ at§u§vaSes'st‘;_. ixacludirrg nammg zine enflre invantive eniityz must acrsompami this form
`gm mus: have been preuiwséy flied. Use:-.m adéificnal P‘{O;’A}A/331 form for each addétéanai §n\.'e§‘:E0r.
`
`
`in a benefit by the Lxubiic which is to fife (and
`This culisrfiian ofinfmmaiiun is re:gu§z=:~c!"by (~15 1.3.3.
`: lsand 3? C‘ R 1.53. Theinformation
`uirediic obtain or :19
`by (he L3:’:3PTQ ta qprmxsss} an aw:-kicarjon. {3v:«nfidenfia}5t3' is gcvemeé by 35
`122 and 3‘? CFR 1.11 and ‘E.-‘M. This cgviisceinax is esfimateditc faka 1
`ta
`cqmrsieia, End-«ding <_:a£‘hefing, ;:re§:aring, and submitting; the mznpieksd
`.a‘a'cn farm to the USPTO. T§rm‘.- wifl vary dependérsg upon ‘J:
`ndividuai case. Any
`3:5
`
`ccmrneents on. the anmunt us‘ time yw raquire to mmpiete this form asso‘!or suggrswans for reducing; this burden. shcuio‘ be ssnt m the C.
`in;'r:-
`'
`V 0557869’, US,
`
`Pfzteni ancf Trademark Oifice, UL.‘-3. Eiepazimafii cf Commerce, PK}. Box $450, Ataxandfis, \«‘.'?\. 2231341450, DO NOT SEND FEES QR .(3C)’~V!!-“-{.iIx
`E) F’OR§~1§S TO
`TE-:3S~.'\Bi3F>.E$.S. SENFZB TS: {'33-mméss‘-‘aims-:3? fur Psi-M359 RD. Bax 135$}, Aiestands-ia, VA .i§2.33'i3’»‘§z$5s'¢,
`I;"yoL.f (yea-5‘ assistance in completing the mrrn, oak‘ '!~;3a(»PTO-9199 and safest options.
`61381 7Eé27L<i0t.
`
`
`mericxu 1.eg2£V‘e-3, ':’ess:‘.‘ , . \ .
`
`
`
`
`Pao_:jeW1"T2 "
`
`Page 12
`
`

`
`PTOIAIA/01 (06-12)
`.
`Approved for use through (l1l31I2014. OMB 0651-0032
`US. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
`.
`.
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING. A
`‘
`APPLICATION DATA SHEET (37 CFR 1.76)
`'
`_
`'
`
`’;I,IfI,§,.,‘.fl',,,, A NOVEL FORMULATION or= DICLOFENAC
`
`As the below named inventor, l hereby declare that:
`
`This declaration
`is directed to:
`I
`
`K1
`
`The attached application, or
`,
`_
`_
`.
`-
`i:I United States application or PCT international application number
`
`fired on
`
`The above—identified application was made or authorizedto be made by me.
`
`'I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.
`
`I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001.
`by fine or imprisonment of not more than five (5) years, or both.
`
`_ WARNING:
`Petitionerlapplicant is cautioned to avoid submitting personal information in documents filed in a patent application that may
`contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers .
`(other than acheck or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO
`to support a petition or an application. Ifthis type of personal information is included in documents submitted to the USPTO,
`petitionerslapplicants should consider redacting such personal information from the documents before submitting them to the ’
`USPTO. Petitionerlapplicant is advised that the record of a patent application is available to the public after publication of the
`application (unless a non-publication request in compiiance with 37 CFR ‘|.213(a) is made in the application) or issuance of a
`patent. Furthermore, the record from an abandoned application may also be available to the public if the application is
`referenced in a published application or an issued patent.(see 37 CFR 1.14); Checks and credit card authorization forms
`PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.
`
`LEGAL NAME OF INVENTOR ’
`
`inventor:
`
`Felix Meiseré
`
`»
`
`.
`
`.
`
`Date (Optional) :
`
`-
`
`' Signature:
`
`Note: An application data sheet (PTOISBI14 or equivalent), including-naming the entire inventive entity, must accompany this form
`or must have been previously filed . Use an -additional‘ PTOIAIAIO1 form for each additional inventor.
`
`This collection of information is required by 35 U.S.C, 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to tile (and
`' by the USPTO to process) an application. Confidentiality is governed by 35 U.S.G. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to lake 1 minute to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending‘ upon the individual case. Any
`comments on the amount of time you require to complete this form andior suggestions for reducing this burden, should be sent tothe Chief Information Otficar, U.S.
`Patent and Trademark Offioe, US. Department of Commerce, P.o. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS To
`THIS ADDRESS. SEND ‘TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA’ 22313-1450.
`,
`'
`-
`ifyou need assistance in completing the form, calf 1-aao—PTos19s and select option 2.
`-
`.
`'
`’
`
`60_s17927.doc
`
`American LegalNet. Inc.
`
`tyym Eogrm~.s‘sVorl:'Flo_t“v_._c_vg"
`
`Page 13
`
`Page 13
`
`

`
`
`
`
`
`
`
`‘Q:33:
`can L..IS.
`
`
`
` -\ 't1\.::: ..
`
`.\‘k
`\-.~
`e-\~\;,v\~\ \ » \~v\,\.~\'\‘ \«\\§¢ .~s
`\\\;;\ {:5-m.~§ \ nu,
`aw _.~ {aw -ax
`‘_...K..\\.\.\MM..\.\.\\.\_.w.,.“....m.....m..\m\.......‘..m....,.....m.\.\,.\.m.~.w....,.,.......\..W.‘..........\.w......~..\....M...\.M.‘.w...\\
`‘
`“ ‘*‘
`=.,-‘:‘..\.~.‘\...~‘>\§‘?.35::=z..~?-\2 ave:
`‘\.-€¢§'~2 Mn !..3§'\
`s~ =\ ~..~:\ ::k
`x
`. ,(.,_W,‘,.\_, .\ N.‘ \\
`...,\..\..
`\
`
`‘'‘-~,..,»/
`,é\é~*.§-‘3..%\.-.\~\.: 5‘\s:‘ is.» :
`w.e...w.\«-V‘
`-. “. « w.‘
`\\\\\ u
`aw.-..u.~.\
`»,~.
`\w\A ..,....... ~\..~.«................w.,......w..u.\-
`wswuswvwvwsxwnu-vus\vI~vr~Invv»\
`\\\\\\\\
`.3}“"2-Ax«aw.wt’:aw»wmmm..w.x\-...-.'.«.u.~.\2¢R§'§-.u\uuu§§}}¥.l§5.=-nu.-.=§-on-.:.s~$~»-uuu-.».:.~.,..“».,..m\s.u»..\.:’: mm, GEES}!1‘:§...§~&§-3.wu§§2«§~2l‘tt§"s§§‘.»m»w...»~..».‘
`
`
`
`
`
`.,,MM«mm/,mmm»~uu..,,mm......,.w.,.m................,,,,,,,,,,..,,,,,,...,.,.,,.wm.m....Jm......,.,,,,,,,,
`m..W,,,,,,,»,,,,,m,,,..mW,...0,,,,.,.}..m........,...,.,.,,..........,
`
` ,
`.
`«MW...»-M-.“-.we.u~v.-u.\-.\-.--.«.-.xv.\“\\\‘\\\u\\\.uu“.._....\.............um.“.-....w....~...~...~.-.~ww.~w.x\x\\\\\~x\.».\.u“.“ \\uwv»\\\sV\\s\\\\\\-u-um\-n-s\\5\\\\'n'vn\\\\\\\\\\\\'\\\\\\\\
`\\ .\. \»\ N. u
`~» <2“-\ B-3‘
`
`
`
`
`.~.. M.
`».
`‘.9 .3 V»; .
`
`
`
`
`9:” ma‘ -*::~:==§> it
`
`
` 9 \.. §§‘.::;:;‘ "
`
`\.'
`_:,\%~'.~l::-:=.\“
`
`
`i‘-‘§-:‘~-‘b \*‘7>.‘S~*I.*".':3\“-
`~$~, *'
`
`, *2:*.¢‘m ti. .1:
`Via‘:
`. 1:»2l‘\-\:‘»7.‘
`
`
`:":¥:\c.-a:';a\\i ..==
`;\.(\:..
`.;
`\~ “.
`‘.
`~
`\~A~~\
`.
`. -N3 5-\§\~-~ x-:«‘-
`<. ‘.\‘.§.\e.:<_.:
`-
`
`
`533 , 3Z2,353Z537 Esi.i,2,357i522533E395Z515 155iZIg5 ,
`
`
`
`5Z
`
`
`
`
`
`3
`;
`
`
`
`{mam.m,/M»..,....,....%.m
`
`
`
`\\\II\\\\Iw\r~\~AA\I\w\\\M.A\~.v.\mv..s\\\-\n\\-ssnmsm-m\hxxx3\\\\\\\\\\.v~.\r-.v«sun«Axx\-svs\\sv.ss~.-u-v.-us-u-.v.vus\x\\-vsvim5-vn33\\\\\\\\\\\\\\\\\\\AI~.I.\\I.\\IAA\\\\nA~N\~mn~»-v~\~v\\\I~Is-\~In\\\\\M\\\\\\\w~\»|3w~\
`
`‘~.
` :.~.
`V-NN\V\\\\\\\\\“~\\\\\\\K<W-A-\-N-~5‘\~‘4\\V\‘-\'-V~Mr’-V-V>'-'-!\'~\'I=\'\\\'\\\\\\‘<\\\\\\\xv.-.~n\«:u\\w~\.v.\\\\«\.\a.\\xs\:.r.\uo.r.sA».»:.~.s»xmn».»».».».».\\\\h>x\\\\\xuxs-n\\u~nnA»-\s\x\-s~.ssv.\
`.\.«...«
`‘
`‘- w~.;.
`3% ’-'3 C’-'2§&.\\ §
`"'
`B i:\ 31¢
`
`*1x\~> is -rx::~.*.a‘.\~\~ ii‘ t-3.\‘~:
`
`‘
`
` ~:$:n‘§>.;: ~,\¢$x\~>
`'1:‘\~ :«->:¢o::.«‘ -
`
`
`
`4AlCV‘\
`_\:_)_‘ :\ m.\\:&,3;:\.\«»
`
`
`
`Page 14
`
`\
`.
`.
`
`.>‘m\~r:c~.\~:
`K‘-"‘»K\
`;m>.4.~:.:.~.‘.
`4/,'«
`... .. ....,...-.-.~-. u-..
`
`
`
`Page 14
`
`

`
`_
`_
`H ;'.)s2'-,7. ixsde:
`§3acs.:mssn:.£}as»e¢1e;:s:‘ma::
`
`
`__
`
`at :,*§e:«r;§araté:g.m“a§§«::‘
`
`firaons are 2<s;~a;uisa§:§..tn .-'¢'=~;;'.‘~raz‘~;’d £9.
`..4;&=H'~;:- Fag ?'.;£T‘§“s.‘ A ‘ T
`3" ma agxau as: M m&..7;{§m‘a§: